STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Ph 2 Sarcoma Trial of STC‑15 April 21, 2026
Tazverik® (tazemetostat) voluntarily withdrawn in follicular lymphoma and epithelioid sarcoma March 17, 2026
Positive Biomarker Data from Ph 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Announced January 18, 2026
Successful Type C Meeting with US FDA Regarding Ph 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Announced December 22, 2025
Positive Topline Results from Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Reported and Updates Provided on CRC and Ewing Sarcoma Expansion Cohorts October 29, 2025
Xintela’s oncology subsidiary, Targinta AB, and MSK’s Therapeutics Accelerator to develop integrin α10β1 antibody therapeutic in patients with aggressive sarcoma October 15, 2025
FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma October 15, 2025
FDA Fast Track Designation for CLD-201 (SuperNova) for the Treatment of Patients with Soft Tissue Sarcoma August 5, 2025
Elraglusib Clinical Program Advanced in Ewing Sarcoma After Positive Ph 1 Trial Demonstrates CRs and PRs in R/R Ewing Sarcoma July 23, 2025
End of Phase 2 Meeting with FDA scheduled for August 27, 2025 to review OST-HER2 recurrent, pulmonary metastatic osteosarcoma program July 15, 2025
End of Ph 2 Meeting Granted by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma July 8, 2025
Statistically Significantly Positive 1-Year EFS, OS, and Safety Clinical Data Updates for OST-HER2 in osteosarcoma patients July 1, 2025
80% ORR reported in injected tumours in Stage 1 of Ph 2a trial of tigilanol tiglate for Soft Tissue Sarcoma July 1, 2025
Positive Topline Efficacy Results Reported from Ph 1B/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Mets (MB-107) June 10, 2025
Efti with Radiotherapy & KEYTRUDA Meets Primary Endpoint in Ph 2 for Soft Tissue Sarcoma June 3, 2025
US FDA grants Orphan Drug Designation to THE001 for the treatment of soft tissue sarcomas (STS) May 13, 2025
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals February 4, 2025
Ph 1 SB101 Trial expanded to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas January 28, 2025
US FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS) January 15, 2025
GSK’227 receives US FDA Breakthrough Therapy Designation in late-line R/R osteosarcoma January 15, 2025
